VEGFA and diabetic macular edema: In another study to assess the real world management of diabetic macular edema (DME), it was observed that subjects presented with better visual acuity (VA) at presentation received no treatment but those presented with lower VA at index date were promptly treated with anti-VEGF which improved the VA at end of 1 year, and further patients who received > 5 injections per year had a better VA gain compared to those who received 1–5 injections during the same period [16].